Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis. METHODS: We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered subcutaneously at baseline, week 4, and week 8, as compared with placebo, in patients with moderate-to-severe prurigo nodularis and severe pruritus. Moderate-to-severe prurigo nodularis was defined as 20 or more nodules, and severe pruritus was defined as a mean score of at least 7 for the worst daily intensity of pruritus on the numerical rating scale (scores range from 0 [no itch] to 10 [worst itch imaginable]). The primary outcome was the percent change from baseline in the mean peak score for pruritus on the numerical rating scale at week 4. Secondary outcomes included additional measures of itching and disease severity. Safety assessments were performed through week 18. RESULTS: A total of 70 patients were randomly assigned in a 1:1 ratio to receive nemolizumab (34 patients) or placebo (36). The initial pruritus score on the numerical rating scale was 8.4 in each group. At week 4, the peak pruritus score on the numerical rating scale was reduced from baseline by 4.5 points (change, -53.0%) in the nemolizumab group, as compared with a reduction of 1.7 points (change, -20.2%) in the placebo group (difference, -32.8 percentage points; 95% confidence interval, -46.8 to -18.8; P<0.001). Results for secondary outcomes were in the same direction as for the primary outcome. Nemolizumab was associated with gastrointestinal symptoms (abdominal pain and diarrhea) and musculoskeletal symptoms. CONCLUSIONS: Nemolizumab resulted in a greater reduction in pruritus and severity of skin lesions than placebo in patients with prurigo nodularis but was associated with adverse events. Larger and longer trials are needed to determine the durability and safety of nemolizumab for the treatment of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT03181503.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, nemolizumab generated promising results in prurigo nodularis, a highly pruritic skin disorder assumed to be related to AD193.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [193]
In the citing paper
“However, this conclusion may not be generalized for a number of itchy skin disorders such as prurigo nodularis in which targeting itch remains promising193,205,210–212.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [193]
Citations
Cites
IL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Pereira, M. P., Steinke, S., Zeidler, C., Forner, C., Riepe, C., Augustin, M., Bobko, S., Dalgard, F., Elberling, J., Garcovich, S., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14570 · Cited by 274
Self-citationEthnic differences and comorbidities of 909 prurigo nodularis patients
Boozalis, E., Tang, O., Patel, S., Semenov, Y. R., Pereira, M. P., Stander, S., Kang, S., & Kwatra, S. G. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.047 · Cited by 189
Self-citationIL-31: A new key player in dermatology and beyond
Bağci, I. S., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.045 · Cited by 160
Chronic Prurigo of Nodular Type: A Review
Zeidler, C., Tsianakas, A., Pereira, M. P., Ständer, H. F., Yosipovitch, G., & Ständer, S. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2774 · Cited by 126
Self-citationPrurigo Nodularis and Its Management
Zeidler, C., Yosipovitch, G., & Ständer, S. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.003 · Cited by 112
Self-citationSteinke, S., Zeidler, C., Riepe, C., Bruland, P., Soto‐Rey, I., Storck, M., Augustin, M., Ивановна, Б. С., Garcovich, S., Legat, F. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.044 · Cited by 104
Self-citationItch in dermatomyositis: the role of increased skin interleukin-31
Kim, H. J., Zeidi, M., Bonciani, D., Pena, S. M., Tiao, J., Sahu, S., & Werth, V. P. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16498 · Cited by 94
The pathogenesis of Prurigo nodularis – ‘Super‐Itch’ in exploration
Zeidler, C., & Ständer, S. (2016) · European Journal of Pain · doi:10.1002/ejp.767 · Cited by 91
Self-citationBrenaut, E., Halvorsen, J. A., Dalgard, F. J., Lien, L., Balieva, F., Sampogna, F., Linder, D., Evers, A. W. M., Jemec, G. B. E., Gieler, U., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15145 · Cited by 85
Self-citation
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Self-citationWollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationA basophil-neuronal axis promotes itch
Wang, F., Trier, A. M., Li, F., Kim, S., Chen, Z., Chai, J. N., Mack, M. R., Morrison, S. A., Hamilton, J. D., Baek, J., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.033 · Cited by 264
Interleukin‐31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M., & Buddenkotte, J. (2021) · Allergy · doi:10.1111/all.14791 · Cited by 228
Self-citationPhase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Kwatra, S. G., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C., Simon, D., Naldi, L., Lynde, C., De Bruin-Weller, M. S., Nahm, W. K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301333 · Cited by 193
Self-citationUnderstanding human mast cells: lesson from therapies for allergic and non-allergic diseases
Kolkhir, P., Elieh-Ali-Komi, D., Metz, M., Siebenhaar, F., & Maurer, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00622-y · Cited by 193
Neuroimmune communication regulating pruritus in atopic dermatitis
Steinhoff, M., Ahmad, F., Pandey, A., Datsi, A., AlHammadi, A., Al-Khawaga, S., Al-Malki, A., Meng, J., Alam, M., & Buddenkotte, J. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.03.010 · Cited by 190
Self-citationWilliams, K. A., Huang, A. H., Belzberg, M., & Kwatra, S. G. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.182 · Cited by 183
Pruritus as a Distinctive Feature of Type 2 Inflammation
Garcovich, S., Maurelli, M., Gisondi, P., Peris, K., Yosipovitch, G., & Girolomoni, G. (2021) · Vaccines · doi:10.3390/vaccines9030303 · Cited by 168
“In line with a central role of Th2 cytokines, blocking the IL-4/13 or IL-31 signaling pathways, respectively, with dupilumab or nemolizumab, demonstrated short- and long-term efficacy in treating PN [87,88].”
BackgroundSelf-citationType 2 chronic inflammatory diseases: targets, therapies and unmet needs
Kolkhir, P., Akdiş, C. A., Akdiş, M., Bachert, C., Bieber, T. R. M., Canonica, G. W., Guttman‐Yassky, E., Metz, M., Mullol, J., Palomares, Ó., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00750-1 · Cited by 195
Self-citationItch: A Paradigm of Neuroimmune Crosstalk
Wang, F., & Kim, B. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.008 · Cited by 129
Elmariah, S. B., Kim, B., Berger, T. G., Chisolm, S., Kwatra, S. G., Mollanazar, N. K., & Yosipovitch, G. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.07.025 · Cited by 126
Self-citationButler, D. C., Berger, T. G., Elmariah, S. B., Kim, B., Chisolm, S., Kwatra, S. G., Mollanazar, N. K., & Yosipovitch, G. (2024) · JAMA · doi:10.1001/jama.2024.4899 · Cited by 147
Self-citationInterleukin-31 as a Clinical Target for Pruritus Treatment
Kabashima, K., & Irie, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.638325 · Cited by 127
“Based on the positive results of the recent phase 3 clinical trial of nemolizumab plus concomitant topical agents to treat patients with atopic dermatitis and moderate-to-severe pruritus (103), and the efficacy benefits shown in reducing pruritus in patients with moderate-to-severe prurigo nodularis (104), this drug a…”
BackgroundMisery, L., Pierre, O., Gall‐Ianotto, C. L., Lebonvallet, N., Chernyshov, P. V., Garrec, R. L., & Talagas, M. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.05.004 · Cited by 128
Self-citationMeng, J., Li, Y., Fischer, M. J. M., Steinhoff, M. S., Chen, W., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696784 · Cited by 117
Hashimoto, T., Nattkemper, L. A., Kim, H. S., Kursewicz, C. D., Fowler, E., Shah, S. M., Nanda, S., Fayne, R. A., Paolini, J. F., Romanelli, P., et al. (2021) · Experimental Dermatology · doi:10.1111/exd.14279 · Cited by 112
Self-citationSofen, H., Bissonnette, R., Yosipovitch, G., Silverberg, J. I., Tyring, S., Loo, W. J., Zook, M., Lee, M., Zou, L., Jiang, G.-L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101826 · Cited by 108
Self-citationNemmer, J., Kuchner, M., Datsi, A., Oláh, P., Julia, V., Raap, U., & Homey, B. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.639097 · Cited by 107
“Recently, phase two clinical trials demonstrated therapeutic efficacy of the neutralizing IL-31RA antibody nemolizumab in patients suffering from atopic dermatitis or prurigo nodularis (2, 3).”
BackgroundTranscriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab
Tsoi, L. C., Hacini‐Rachinel, F., Fogel, P., Rousseau, F., Xing, X., Patrick, M. T., Billi, A. C., Berthier, C. C., Kahlenberg, J. M., Lazzari, A., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.10.004 · Cited by 106
Self-citationBreaking the Itch–Scratch Cycle in Prurigo Nodularis
Kwatra, S. G. (2020) · New England Journal of Medicine · doi:10.1056/nejme1916733 · Cited by 94
Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization
Belzberg, M., Alphonse, M. P., Brown, I. D., Williams, K. A., Khanna, R., Ho, B. K., Wongvibulsin, S., Pritchard, T., Roh, Y. S., Sutaria, N. H., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.02.749 · Cited by 101
Kim, B., Rothenberg, M. E., Sun, X., Bachert, C., Artis, D., Zaheer, R. S., Deniz, Y. M., Rowe, P., & Cyr, S. L. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.017 · Cited by 99
“…type 2 inflammation include biologics that target cytokines or their receptors, including dupilumab, lebrikizumab, nemolizumab, tralokinumab, omalizumab, mepolizumab, reslizumab, benralizumab, tezepelumab, and vixarelimab, 17,20–36, 52 ,133,134,137,139, 170– 177, 202– 209, 215– 217 as well as JAKIs”
The use of biologics in food allergy
Fiocchi, A. G., Vickery, B. P., & Wood, R. A. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13897 · Cited by 96
Itch in Atopic Dermatitis – What Is New?
Legat, F. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644760 · Cited by 82
“In addition, the extent of healed nodular skin lesions was significantly better than that seen in controls (68).”
BackgroundSelf-citationAlkon, N., Assen, F. P., Arnoldner, T., Bauer, W. M., Medjimorec, M. A., Shaw, L. E., Rindler, K., Holzer, G., Weber, P. B., Weninger, W. J., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.04.019 · Cited by 87
Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis
Williams, K. A., Roh, Y. S., Brown, I. D., Sutaria, N. H., Bakhshi, P. R., Choi, J., Gabriel, S., Chavda, R., & Kwatra, S. G. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1852080 · Cited by 85
New and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Fassett, M. S., Bráz, J. M., Castellanos, C. A., Salvatierra, J. J., Sadeghi, M., Yu, X., Schroeder, A., Caston, J., Muñoz-Sandoval, P., Roy, S., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abi6887 · Cited by 86
“This expression pattern links skin inflammation with neurosensory pathways that mediate itch and suggests that IL-31 could be a promising therapeutic target in a growing number of itchy inflammatory skin diseases including atopic dermatitis (AD) and prurigo nodularis (3, 4).”
BackgroundChronic Prurigo Including Prurigo Nodularis: New Insights and Treatments
Müller, S., Zeidler, C., & Ständer, S. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00818-z · Cited by 83
“The most common AEs in the nemolizumab group were gastrointestinal symptoms (21% of patients), musculoskeletal or connective-tissue symptoms (18% of patients) and bronchitis (6% of patients) [72].”
BackgroundInfluentialSelf-citationPrevalence, pathophysiology and management of itch in epidermolysis bullosa*
Papanikolaou, M., Onoufriadis, A., Mellerio, J. E., Nattkemper, L. A., Yosipovitch, G., Steinhoff, M. S., & McGrath, J. A. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19496 · Cited by 83
Self-citationKwatra, S. G., Misery, L., Clibborn, C., & Steinhoff, M. S. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1390 · Cited by 78
“In addition, promising results have been seen with nemolizumab in prurigo nodularis.(37) Oncostatin M (OSM), which is produced by dermal T cells and monocytes, is a highly”
BackgroundSelf-citationSensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch
Takahashi, S., Ochiai, S., Jin, J., Takahashi, N., Toshima, S., Ishigame, H., Kabashima, K., Kubo, M., Nakayama, M., Shiroguchi, K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113433 · Cited by 73
Schön, M. P., Berking, C., Biedermann, T., Buhl, T., Erpenbeck, L., Eyerich, K., Eyerich, S., Ghoreschi, K., Goebeler, M., Ludwig, R. J., et al. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14169 · Cited by 71
Keam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01741-z · Cited by 68
“2.3.1.3 Prurigo Nodularis Nemolizumab monotherapy significantly improved pruritus symptoms in patients with moderate-to-severe PN and severe pruritus in a phase 2 placebo-controlled trial (NCT03181503) [23].”
BackgroundInfluentialStänder, S., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C. F., Simon, D., Naldi, L., Metz, M., Tsianakas, A., Pink, A., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.4796 · Cited by 66
Self-citationKolkhir, P., Pyatilova, P., Ashry, T., Jiao, Q., Abad‐Perez, A. T., Altrichter, S., Vera, C., Church, M. K., He, J., Lohse, K., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.02.021 · Cited by 63
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis
Kremer, A. E., Mayo, M. J., Hirschfield, G. M., Levy, C., Bowlus, C. L., Jones, D. E., Johnson, J. D., McWherter, C. A., & Choi, Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000728 · Cited by 67
Immunosensation: Neuroimmune Cross Talk in the Skin
Tamari, M., Heul, A. V., & Kim, B. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101719-113805 · Cited by 64
Interleukin-31 and Pruritic Skin
Furue, M., & Furue, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091906 · Cited by 64
“Nemolizumab (anti-IL-31RA), [11] Moderate to severe prurigo nodularis (phase 2) Significant reduction of pruritus (−53% in 0.”
BackgroundHusein‐ElAhmed, H., & Steinhoff, M. S. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1853024 · Cited by 62
Ma, F., Gharaee‐Kermani, M., Tsoi, L. C., Plazyo, O., Chaskar, P., Harms, P. W., Patrick, M. T., Xing, X., Hile, G. A., Piketty, C., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.07.005 · Cited by 61
Self-citationWeisshaar, E., Szepietowski, J., Bernhard, J., Hait, H., Legat, F., Nattkemper, L., Reich, A., Sadoghi, B., Sciascia, T., Zeidler, C., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17816 · Cited by 34
Self-citationLichen Simplex Chronicus Itch: An Update
Ju, T., Does, A. V., Mohsin, N., & Yosipovitch, G. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.4367 · Cited by 65
“Nemolizumab, a monoclonal antibody targeting the IL-31 receptor, was found to be effective in reducing pruritus and severity of skin lesions in PN in a randomized clinical trial of 70 patients (37).”
BackgroundSelf-citationMolecular mechanisms of pruritus in prurigo nodularis
Shao, Y., Wang, D., Zhu, Y., Xiao, Z., Jin, T., Peng, L., Shen, Y., & Tang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1301817 · Cited by 63
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances
Ständer, S., Yosipovitch, G., Lacour, J. ‐., Legat, F. J., Paul, C. F., Reich, A., Chaouche‐Teyara, K., Ahmad, F., & Piketty, C. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18377 · Cited by 50
Self-citationImmunotargets and Therapy for Prurigo Nodularis
Labib, A., Ju, T., Does, A. V., & Yosipovitch, G. (2022) · ImmunoTargets and Therapy · doi:10.2147/itt.s316602 · Cited by 54
“One phase II randomized, double-blind clinical trial was conducted over a 12-week trial where nemolizumab was administered subcutaneously every 4 weeks in patients with moderate-to-severe PN and pruritus.(78) Results revealed that average itch numerical rating scores (NRS) were significantly reduced by about 53%.”
BackgroundSelf-citationThe evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective
David, E., Ungar, B., Renert‐Yuval, Y., Facheris, P., DUCA, E. D., & Guttman‐Yassky, E. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14263 · Cited by 52
Misery, L. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21698 · Cited by 49
Self-citationProminent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis
Belmesk, L., Muntyanu, A., Cantin, E., Alhalees, Z., Jack, C. S., Le, M., Sasseville, D., Iannattone, L., Ben‐Shoshan, M., Litvinov, I. V., et al. (2021) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754211027858 · Cited by 51
Sutaria, N. H., Alphonse, M. P., Marani, M., Parthasarathy, V., Deng, J., Wongvibulsin, S., Williams, K. A., Roh, Y. S., Choi, J., Bordeaux, Z. A., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.10.011 · Cited by 49
The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis
Janmohamed, S. R., Gwillim, E. C., Yousaf, M., Patel, K. R., & Silverberg, J. I. (2020) · Archives of Dermatological Research · doi:10.1007/s00403-020-02148-0 · Cited by 43
“Stander 2020 [28] RCT 70 Placebo NRS-itch VRS-itch DLQI Phase II study with nemolizumab for moderate-to-severe PN.”
BackgroundMethodInfluentialPathophysiology of Prurigo Nodularis: Neuroimmune Dysregulation and the Role of Type 2 Inflammation
Kwatra, S. G., Ständer, S., Yosipovitch, G., Kim, B., Levit, N. A., & O’Malley, J. T. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.06.1276 · Cited by 50
Self-citationPrurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics
Yook, H. J., & Lee, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105164 · Cited by 48
“In an open-label clinical study, a moisturizing cream containing the CB2 agonist N-palmitoyl ethanolamide (Figure 2D) significantly alleviated itching in eight out of twelve patients with PN [45,224].”
BackgroundGründel, S., Pereira, M. P., Storck, M., Osada, N., Schneider, G., Ständer, S., & Zeidler, C. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3571 · Cited by 41
“With regard to novel drugs for treatment of CNPG the neurokinin-1 receptor antagonist serlopitant (5) and the anti-IL-31 receptor A-antagonist nemolizumab reduced pruritus in patients with CNPG in phase II trials (28).”
BackgroundSelf-citationChronic Nodular Prurigo: An Update on the Pathogenesis and Treatment
Wong, L., & Yen, Y.-T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012390 · Cited by 48
“A phase 2 clinical trial included 70 patients demonstrated a significant reduction in the peak pruritus scores by 4.5 points in the nemolizumab group (0.5 mg/kg) in comparison with a reduction by 1.7 points in the placebo group at 4-week treatment (NCT03181503) [111].”
BackgroundInfluentialPereira, M. P., Zeidler, C., Wallengren, J., Halvorsen, J., Weißhaar, E., Garcovich, S., Misery, L., Brenaut, E., Şavk, E., Потекаев, Н. Н., et al. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3726 · Cited by 39
“se/acta efficacy of nemolizumab in CNPG showed promising results (9), while case series suggest a good anti-pruritic effect of dupilumab (11, 27, 28).”
BackgroundSelf-citationPatel, J. R., Joel, M. Z., Lee, K. K., Kambala, A., Cornman, H. L., Oladipo, O. O., Taylor, M. T., Imo, B. U., Ma, E. Z., Manjunath, J., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.12.021 · Cited by 45
Emerging Therapeutic Options for Chronic Pruritus
Reszke, R., Krajewski, P. K., & Szepietowski, J. C. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00534-y · Cited by 41
Treatment of patients with chronic pruritus of unknown origin with dupilumab
Jeon, J., Wang, F., Badic, A., & Kim, B. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1880542 · Cited by 36
“The first pruritogenic cytokine, IL-31, is now a biologic target for nemolizumab (antiIL-31RA mAb) in atopic dermatitis and prurigo nodularis (6,7), and has recently been shown to be elevated in the sera of patients with CPUO (8).”
BackgroundIncreased cardiovascular risks and mortality in prurigo nodularis: a global cohort study
Olbrich, H., Kridin, K., Hernández, G., Zirpel, H., Sadik, C. D., Terheyden, P. A. M., Thaçi, D., Ludwig, R. J., & Boch, K. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105123 · Cited by 35
“24 In previous smaller retrospective studies, several cardiac and vascular diseases were found to be more frequent in patients with PN compared to patients with AD or psoriasis including hypertension and ischaemic heart disease.”
ResultTraidl‐Hoffmann, C., Afghani, J., Akdiş, C. A., Akdis, M., Aydin, H., Baerenfaller, K., Behrendt, H., Bieber, T. R. M., Bigliardi, P. L., Bigliardi‐Qi, M., et al. (2024) · Allergy · doi:10.1111/all.16247 · Cited by 41
“26 Both cytokines, IL-4 and IL-13, use the Type 2 IL-4 alpha receptor.”
Self-citationParthasarathy, V., Cravero, K., Deng, J., Sun, Z., Engle, S., Auxier, A. N., Hahn, N., Sims, J. T., Okragly, A. J., Alphonse, M. P., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1011142 · Cited by 34
“Additional evidence of varying degrees of type 2 inflammatory dysregulation clinically includes highly variable levels of blood eosinophils and IgE, which serve as predictors of response to immunomodulatory therapy in other chronic pruritic conditions such as chronic pruritus of unknown origin (26, 27).”
BackgroundThe translational revolution of itch
Kim, B. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.031 · Cited by 35
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies
Trier, A. M., & Kim, B. (2022) · British Journal of Dermatology · doi:10.1093/bjd/ljac016 · Cited by 33
Calcium Channels: Noteworthy Regulators and Therapeutic Targets in Dermatological Diseases
Wang, M., Sun, Y., Li, L., Wu, P., Ocansey, D. K. W., & Shi, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.702264 · Cited by 37
Impact of Itch on Sleep Disturbance in Patients with Prurigo Nodularis
Gwillim, E. C., Nattkemper, L. A., & Yosipovitch, G. (2021) · Acta Dermato Venereologica · doi:10.2340/00015555-3778 · Cited by 30
“A welldesigned 12-week randomized controlled trial (RCT) of nemolizumab involving 70 patients also used a NRS (values from 0 to 10) and found numerical improvements in sleep quality starting at week 1 after the first treatment and at week 4 (15).”
MethodSelf-citationIL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses
Roh, Y. S., Choi, J., Sutaria, N. H., Belzberg, M., Kwatra, M. M., & Kwatra, S. G. (2021) · Drugs · doi:10.1007/s40265-021-01521-1 · Cited by 31
“A recent 12-week, randomized, double-blind, parallel-group phase II trial of nemolizumab in moderateto-severe PN patients [109] found that at week 4, there was 53% reduction in numeric pruritus score in the nemolizumab group versus 20.”
BackgroundTherapeutic potential of biologics in prurigo nodularis
Müller, S., Bieber, T. R. M., & Ständer, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1958777 · Cited by 33
Self-citationAgrawal, D. R., Sardana, K., Mathachan, S. R., Bhardwaj, M., Ahuja, A., & Jain, S. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14709 · Cited by 29
Emerging concepts in neuropathic and neurogenic itch
Auyeung, K. L., & Kim, B. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.08.008 · Cited by 31
Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review
Selman, C. J., Lee, K. J., Ferguson, K. N., Whitehead, C. L., Manley, B. J., & Mahar, R. K. (2024) · Trials · doi:10.1186/s13063-024-08072-2 · Cited by 39
Neuron‒Mast Cell Cross-Talk in the Skin
Zhang, S., Sumpter, T. L., & Kaplan, D. H. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.10.006 · Cited by 31
Serra‐Baldrich, E., Santamaria‐Babí, L. F., & Silvestre, J. F. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.12.014 · Cited by 31
Deng, J., Liao, V., Parthasarathy, V., Cornman, H. L., Kambala, A., Kwatra, M. M., Ständer, S., Piketty, C., Chaskar, P., Krishnaswamy, J. K., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.2609 · Cited by 27
Self-citationSchön, M. P., Berking, C., Biedermann, T., Buhl, T., Erpenbeck, L., Eyerich, K., Eyerich, S., Ghoreschi, K., Goebeler, M., Ludwig, R. J., et al. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14169_g · Cited by 28
Świerczyńska-Mróz, K., Krajewski, P. K., Nowicka‐Suszko, D., Białynicki‐Birula, R., Krajewska, M., & Szepietowski, J. C. (2022) · Toxins · doi:10.3390/toxins14030197 · Cited by 30
“Similar effects of nemolizumab were found in a group of patients with prurigo nodularis [30].”
European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)
Weißhaar, E., Müller, S., Szepietowski, J. C., Dalgard, F. J., Garcovich, S., Kupfer, J. P., Giménez‐Arnau, A. M., Lambert, J. R., Mettang, T., Misery, L., et al. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.44220 · Cited by 38
Self-citationThe pruritogenic role of the type 2 immune response in diseases associated with chronic itch
Ingrasci, G., Lipman, Z. M., Hawash, A. A., Girolomoni, G., & Yosipovitch, G. (2021) · Experimental Dermatology · doi:10.1111/exd.14401 · Cited by 30
Self-citationDoes, A. V., Ju, T., Mohsin, N., Chopra, D., & Yosipovitch, G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108355 · Cited by 28
Self-citationLiang, J., Hu, F., Dan, M., Sang, Y., Abulikemu, K., Wang, Q., Hong, Y., & Kang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.825312 · Cited by 27
“Stander, 2020 (29) Multinational 2 18 3 Q4W 0.”
Meixiong, J., Dong, X., & Weng, H.-J. (2020) · Cells · doi:10.3390/cells9102263 · Cited by 31
Type 2 Inflammation and Its Role in Dermatologic Diseases
Chovatiya, R., Hawkes, J. E., DiRuggiero, D., Pansch, L. A., Simcox, E., & Gonzalez, T. (2025) · International Journal of Dermatology · doi:10.1111/ijd.17707 · Cited by 30
“Nemolizumab, also approved for PN, targets the IL-31 receptor and has been associated with improvements in PN lesions and pruritus in phase 2 and 3 trials [88, 90, 91].”
Biologics for Atopic Dermatitis
Boguniewicz, M. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.06.004 · Cited by 24
Chronic Itch of Unknown Origin Is Associated With an Enhanced Th2 Skin Immune Profile
Dehner, C. A., Chen, L., Kim, B., & Rosman, I. S. (2021) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001902 · Cited by 25
Cutaneous neuroimmune crosstalk in pruritus
Agelopoulos, K., Pereira, M. P., Wiegmann, H., & Ständer, S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.03.005 · Cited by 30
Self-citationA Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis
Vasavda, C., Wan, G., Szeto, M. D., Marani, M., Sutaria, N. H., Rajeh, A. A., Lu, C., Lee, K. K., Nguyen, N., Adawi, W., et al. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.04.033 · Cited by 25
Prurigo nodularis: disease burden, clinical features and approach to management
Kwatra, S. G., Pereira, M. P., Misery, L., Mollanazar, N. K., Shah, P., & Wiggins, S. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf213 · Cited by 23
Self-citationYokozeki, H., Murota, H., Matsumura, T., Komazaki, H., for the Nemolizumab-JP11 Study Group, Abe, M., Abe, R., Amano, H., Ansai, S., Arase, N., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae131 · Cited by 22
Cutaneous Adverse Events Following Nemolizumab Administration: A Review
Mima, Y., Yamamoto, M., & Iozumi, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093026 · Cited by 23
Parthasarathy, V., Cravero, K., Xu, L., Deng, J., Sun, Z., Engle, S., Sims, J. T., Okragly, A. J., & Kwatra, S. G. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.01.042 · Cited by 23
Pala, V., Rosset, F., Mastorino, L., Sciamarrelli, N., Boskovic, S., Borriello, S., Bongiovanni, E., Crespi, O., Ribero, S., & Quaglino, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110720 · Cited by 25
Gael, M., Adam, T., Mariano‐Bourin, M., & Bursztejn, A. ‐. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18221 · Cited by 21
Roy, Y. R. L., Ficheux, A., Misery, L., & Brenaut, E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1079323 · Cited by 28
“Nemolizumab has a major effect on pruritus; thus, this treatment is also under development in chronic prurigo, with a phase II randomized controlled trial demonstrating efficacy compared with placebo, and 2 phase III trials are also in progress (70).”
BackgroundSelf-citationAquino, T. M., Calvarido, M. G. A., & North, J. P. (2021) · Journal of Cutaneous Pathology · doi:10.1111/cup.14115 · Cited by 20
“Furthermore, successful treatment with the anti-IL-4 receptor drug duplimumab and the anti-IL-31 monoclonal antibody nemolizumab also support Th2 involvement.(20,21) Our results showing upregulated”
BackgroundHu, M., Scheffel, J., Komi, D. E. A., Maurer, M., Hawro, T., & Metz, M. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01141-x · Cited by 21
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
Waligóra-Dziwak, K., Dańczak‐Pazdrowska, A., & Jenerowicz, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144001 · Cited by 23
“When safety is considered, on the basis of meta-analysis [50] (which comprised 569 subjects who were administered nemolizumab and 240 patients receiving placebo), considering six studies analyzed [69,79–83], it might be concluded that nemolizumab is characterized by generally good tolerability.”
MethodSutaria, N. H., Marani, M., Choi, J., Roh, Y. S., Parthasarathy, V., Deng, J., Bordeaux, Z. A., Taylor, M. T., Lee, K. K., Pritchard, T., et al. (2022) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2022.02.004 · Cited by 19
Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments
Bewley, A., Homey, B., & Pink, A. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00782-2 · Cited by 21
“Further, there was statistical separation between groups in favor of nemolizumab in reduction of pruritus scores as soon as week 1 after administration [27].”
BackgroundInfluentialSuccessful treatment of prurigo nodularis with tofacitinib: The experience from a single center
Liu, T., Chu, Y., Wang, Y., Zhong, X., Yang, C., Bai, J., Fang, H., & Qiao, J. (2022) · International Journal of Dermatology · doi:10.1111/ijd.16568 · Cited by 19
Metadata
- Authors
- Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., Ahmad, F., & Piketty, C.
- Affiliations
- University Hospital Bonn (DE)
- University of Graz (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-20
- Volume
- 382
- Issue
- 8
- Pages
- 706-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3008008049
- Cited by
- 281
- References
- 18
- Citations by year
- 2026: 22 · 2025: 36 · 2024: 39 · 2023: 63 · 2022: 40 · 2021: 52 · 2020: 28
- FWCI
- 33.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nestle Skin Health
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Keywords
- prurigo nodularis, nemolizumab, monoclonal antibodies, pruritus, skin lesions, adverse events, gastrointestinal symptoms, musculoskeletal symptoms, treatment safety, treatment efficacy, numerical rating scale
- MeSH terms
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Injections, Subcutaneous, Male, Middle Aged, Muscular Diseases, Prurigo, Pruritus, Young Adult, Antibodies, Monoclonal, Humanized, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.